Collegium Pharmaceutical Inc (COLL) Income Statement
An income statement shows a company's revenue, expenses, and profit over a reporting period.
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.
Total Revenue Chart for Collegium Pharmaceutical Inc
Collegium Pharmaceutical Inc (COLL) revenue for FY2025 was USD 780.6M, a 23.6% change from FY2024. Collegium Pharmaceutical Inc's revenue moved from USD 0.00 in 2014 to USD 780.6M in 2025 over 11 years. Earnings per share moved from USD -2.84 in 2014 to USD -0.74 in 2022. Revenue compound annual growth rate: 5-year CAGR of 20.3%.
Total Revenue (US Dollars)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- $747.48M
- Implied Share Price
- $22.96
- Enterprise Value
- $1.70B
- Revenue (TTM)
- $808.21M
- EBITDA
- $405.26M
- Profit Margin
- 5.93%
- Trailing P/E
- 18.08
- Forward P/E
- 4.79
- Price/Book (MRQ)
- 4.65
- Price/Sales (TTM)
- 0.92
- EV/EBITDA
- 4.87
- EV/Revenue
- 2.39
- Dividend Yield
- —
- Book Value
- $9.60
- Free Cash Flow (FY2025)
- $327.58M
- Free Cash Flow Yield
- 43.83%
Snapshot as of 24th October 2026 — not point-in-time controlled, may lag the live market by a few days.